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Abstract: Stem cells and their potentials for therapy are major areas of research. The literature on the subject
is expanding at a very rapid pace and the great prospectives offered by these remarkable cells are continuously
being unravelled. The use of stem cells vis-à-vis neurological diseases is of particular interest since many such
diseases have a poor prognosis and generally decrease considerably the quality of life. Treatment of
neurological diseases is complicated by the lack of regeneration of the nervous system, the neuroanatomical
complexity, the presence of the blood-brain barrier and the possible spread of excitotoxicity. Hence, more
effective ways how to intervene on these pathological processes are required. This review highlights, the
fundamental aspects of stem cell biology, with a special reference to neural stem cells and their niches.
Dysmyelinating diseases and invasive brain tumours are specifically considered since, they are presumed
candidates for successful clinical application of stem cell therapy.
Key words: Stem cell biology, neural stem cells, neurological diseases, dysmyelinating diseases, genetic
leukodystrophies, lysosomal storage diseases, invasive brain tumours, stem cell therapy
INTRODUCTION ESC divides symmetrically to give 2 identical stem cells,
In 1998, pluripotent stem cells were isolated for the
1st time from early human embryos and grown in culture
(Thompson et al., 1998; Shamblott et al., 1998). The
importance of the long-term proliferation of the Embryonic
Stem Cells (ESCs) and Embryonic Germ Cells (EGCs) was
immediately recognized because it offered the opportunity
to study the genetic  and  molecular  basis  of proliferation
with applications in the understanding of embryological
development, drug development (assessment of
teratogenicity and toxicity) and to yield sufficient
quantities of cells for potential transplantation purposes.
BASIC PROPERTIES OF STEM
CELL BIOLOGY
The 2 basic properties that characterize stem cells are
the long-term self-renewal and multipotency i.e., the
ability to differentiate into many specialized cell types
(NIH Report, 2001a).
Self-renewal of stem cells involves mitotic division
while maintaining pluripotency (Niwa, 2004). Self-renewal
is  postulated  to be indefinite, but it is defined, in
practice, as a proliferation ability, without oncogenic
transformation, well beyond that of somatic cells. The
extent of self-renewal depends on the type of stem cell
and the culture conditions. There are 2 modes of self-
renewal: symmetrical and asymmetrical. For instance, the
while the Adult Stem Cell (ASC) divides asymmetrically to
yield a stem cell and a progenitor cell. 
Pluripotency implies the ability to differentiate into
ectodermal,  mesodermal  and  endodermal  derivatives;
this accounts to >200 cell types. Pluripotency can be
demonstrated in vitro by the formation of embryoid
bodies, which are masses of different types of progenitor
cells from the 3 germ layers. An in vivo test for
pluripotency is teratoma formation upon transplantation
in immunodeficient mice. hESCs are the only stem cells
able to form teratomas. This property implies that ESCs
cannot be used directly for potential therapeutic
applications. 
Stem cells remain uncommitted until appropriate
inducer substances cause induction and cell
determination i.e., the commitment to differentiate. Once
determined, stem cells give rise to progenitor/precursor
cells. These are partially specialized cells, which divide
asymmetrically to generate progenitor and more
specialized cells. Neuroblasts are Neural Progenitor Cells
(NPCs).
The proteome of stem cells is characterized by
components of signalling cascades, cell cycle regulators,
telomerase, chromatin remodelling enzymes, a specialized
post-translatonal regulatory machinery (Vasa type RNA
helicases) and stress-resistance proteins (Johnson and
Andrews, 2004).
Oct-4 is a key transcription factor, which maintains
stem  cells  in  a    proliferative,    non-differentiated   state
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Fig. 1: LIF and the associated Jak/Stat mechanism. A: The 3D structure of murine LIF. It is a long-chain 4 "-helix bundle
cytokine. LIF possesses 3 binding sites. Site I binds to the membrane-proximal Cytokine-Binding Domain (CBD)
of LIFR, site II binds to the CBD of gp130 and site III also binds to the LIFR. B: The LIFR-gp130 complex and its
molecular signalling pathways. Heterodimerization of the LIFR and gp130 upon LIF binding activates Jak activity,
leading to phosphorylation of gp130 and the LIFR. Phosphorylated tyrosine residues on LIFR and gp130 provide
docking sites stat proteins, which are subsequently phosphorylated. The pattern of Jak/Stat protein activation
by LIF is cell type-specific (Auernhammer and Melmed, 2000)
(Pesce and Schöler, 2001). The levels of Oct-4 within a trophoectoderm  lineage  and at increased levels it
given cell seem to govern the commitment along a given induces differentiation along extra-embryonic endoderm
fate; at baseline levels it induces self-renewal, at and  mesoderm   lineages.  An important co-determinant
decreased levels it induces differentiation along the of    pluripotency    is    the     transcription  factor    Nanog
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(Mitsui et al., 2003). Nanog  is found in all pluripotent of  all   three   members  of  t he  pRb  gene  family does
stem  cells  and  endodermal  commitment results in Nanog not compromise ESC  proliferation. Phosphatidylinositol-3
down-regulation. kinase (PI3K) signalling contributes to ESC cycle
Renewal is promoted by extrinsic factors which, via regulation  (Fig.  3).  In  fact,  PI3K inhibition results in an
transcription factors such as Oct-4 and Nanog, modulate
gene expression (Cavaleri and Schöler, 2004). Leukaemia
Inhibitory Factor (LIF) in the only extracellular signal
known to promote self-renewal (Fig. 1). However, it is not
unique in this action. A medium conditioned by parietal
endodermal cells can replace LIF. The exact signal
responsible is not identified and was named ESC renewal
factor (ESCF). Neither LIF, nor ESCF, is sufficient by itself
in maintaining self-renewal. SCF, feeder cells, or high-
density culture conditions (i.e., cell-cell interactions) are
also required.
 ESCs possess particular mechanisms of cell cycle Fig. 2: Principal components of the G1 to S phase
control, different from those of somatic cells (Savatier and checkpoint.   Multiple   CDKs   are  involved  in
Malashicheva, 2004). Genes controlling G1 to S phase the initiation of DNA synthesis via the
transition in response to mitogenic signals are likely to phosphorylation of pRb. D-type cyclins (D1-D3)
underlie proliferation properties of  ESCs  (Fig. 2). G1 and CDK4 and CDK6 (CDK4/6) form during the
phase in ESCs is very short (approximately 1.5 h). preceding G2 phase and their levels fall during S
Hypophosphorylated    retinoblastoma    protein   (pRb) is phase. When pRb is phosphorylated it releases
virtually undetectable in G1 phase. Therefore, in ESCs, E2F, a transcription factor which activates genes
pRB is likely to be rephosphorylated immediately after for enzymes involved in DNA synthesis. Partially
mitosis and does not seem to regulate ESC cycle. phosphorylated pRb, in conjunction with c-myc,
Evidence for this statement comes from the fact that ESCs upregulates its own phosphorylation (Savatier and
are refractory  to  p16 (a CDK inhibitor) and inactivation Malashicheva, 2004)
Fig. 3: The PI3K signal transduction pathway. The actions of PKB, activated via PI3K, include the decrease in the rate
of degradation of cyclin D1 and the increase in the rate of degradation of p27, which inhibits entry into S phase.
Therefore, the PI3K pathway promotes the G1 to S phase transition (Scheid and Woodgett, 2001)
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increase in ESCs in G1 phase and phosphatase and tensin
homolog (PTEN) tumour suppressor gene deficiency
causes an increase in G1 transit (PTEN inhibits PI3K
signalling). ESC PI3K activity may not depend on outside
stimulation. It may be activated by E-ras; ESC growth is
impaired by E-ras deficiency.
ESCs also show p53 dependent apoptosis in case of
irreparable DNA damage. This prevents tumorigenesis
and maintains clonality (Sabapathy et al., 1997).
TYPES OF STEM CELLS
 Stem cells can be conveniently classified in
accordance to their origin (NIH Report, 2001a). ESCs are
derived from the inner cell mass of a 4-5 day blastocyst.
hESCs are maintained in media with 20% foetal calf serum
or serum replacement media supplemented with FGF2.
They also require the presence of feeder cells or
conditioned medium from feeder cells (Carpenter and
Bhatia, 2004). Normal karyotype is maintained over a long
period, but aneuploidy is observed  at  significant levels
in hESC cultures (Roster et al., 2004). Markers used to
characterize hESCs include alkaline phosphatase-related
antigens, stage-specific embryonic antigens 3 and 4
(SSEA-3 and SSEA-4) and tumour rejection antigens 1-60
and 1-81 (Tra-1-60 and Tra-1-81; these are keratin
sulphate-related antigens). 
EGCs are derived from culturing of Primordial Germ
Cells (PGCs) from the gonadal ridge of a 5-10 week foetus
(McLaren, 2004).  PGCs are not stem cells because, as
they divide, they move along the germ cell lineage.
Chromosomally stable EGCs are obtained from PGCs in
culturing medium containing SCF, LIF and FGF2. The
EGCs obtained are imprint-free, as opposed to the PGCs.
SSEA-1 positivity is generally used to differentiate
hEGCs from hESCs. SSEAs are glycolipids of the
globoside type i.e., a ceramide molecule linked to 2 or
more sugar residues. It has been postulated that this
difference may account for the different growth
characteristics. Suggested biological roles of these
glycolipids include regulation of cell growth, recognition
and differentiation during development (Fenderson et al.,
1990). Table 1 summarizes the fundamental distinguishing
features between ESCs and EGCs. 
Stem cells also occur in adult tissues and these are
collectively termed ASCs (Prentice, 2004). ASCs have
limited renewal and differentiation potentials. Note that
ASCs occur even in neonates, umbilical cord and
placenta; thus, terms such as tissue/somatic/post-natal
stem cells would be more accurate expressions to refer to
such cells. Broadly speaking, ASCs yield cells of the
tissue in which they reside. ASCs have been identified in
Table 1: Differences between human embryonic stem cells and human
embryonic germ cells (NIH Report, 2001a)
Feature hESCs hEGCs
SSEA-1 - +
SSEA-3 + +
SSEA-4 + +
TRA-1-60 + +
TRA-1-81 + +
Alkaline phosphatase + +
4-Oct + Unknown
Telomerase activity + Unknown
Feeder cell dependence + +
Factors aiding renewal FGF2 LIF, FGF2, forskolin
Growth characteristics Flat loose aggregates; Rounded multi-layered
in vitro can form Ebs clumps; can form Ebs
Population doublings 300-450 40-80
obtained ion cuture
Teratoma formation + -
in vitro
Chimera formation + -
the CNS, bone marrow, peripheral and umbilical cord
blood, umbilical cord mesenchyme (Wharton’s jelly),
blood vessels, skin and gastrointestinal epithelia, liver,
pancreas, heart, skeletal muscle, tendons, cartilage,
synovial membrane, adipose tissue, corneal limbus, retina,
testes, mammary glands, salivary glands, dental pulp,
thymus and teratocarcinomas (NIH Report, 2001b). ASCs
are quantitatively few and difficult to identify, isolate and
purify. CD133 is generally used as a surface marker of
these cells. Flow cytometry can be employed to isolate
and identify ASCs, exploiting the ability of these cells to
exclude fluorescent dyes via membrane-associated ABC
transporters membrane-associated ABC transporters
(Bunting, 2002).
ASCs exhibit plasticity, they appear to have the
ability of generating specialized cells of tissues other than
their tissue of origin. This is termed transdifferentiation.
Hence, the lineage restrictions of ASCs are not
permanent. For example, haematopoietic stem cells have
been shown to migrate into the brain and develop into
neuron-like cells, oligodendrocytes and astrocytes
(Mezey et al., 2000). Neural Stem Cells (NSCs) also show
plasticity,  they  have  been  found  to  produce cells of
the haematopoietic lineage after in vivo transplantation
(Bjornson et al., 1999). There might also be a ‘universal’
ASC across tissues, which differentiates along tissue-
specific lineages depending on the environmental cues
within the niche in which, it is found (Blau et al., 2001).
While, ESCs exhibit clonality (i.e., they are genetically
identical), ASCs from one particular tissue may not be
clonally-derived (NIH Report, 2001b). This means that
within a particular tissue, instead of having one stem cell
type, which generates the multiple constituent cells, there
may be multiple stem cell types to generate each of the
different cell types. This means that ASC plasticity may
actually be an artifact of poor purification methods.
Lateral ventricle
Fourth
ventricle
Third
ventricle
Subventricular zone along
lateral wall of the lateral
ventricles
Subcortical white matter
Dentate gyrus CA 3
CA 1
(a) (b)
Int. J. Mol. Med. Adv. Sci., 4 (3): 62-73, 2008
66
NEURAL STEM CELLS
Neurogenesis in the adult brain has been shown to
be persistent and functionally relevant (Taupin and Gage,
2002). For example, the Subventricular Zone (SVZ) has
been   shown   to   generate   neuroblasts  that  undergo
a 3-8 mm migration  within  the  rostral  migratory stream
to the olfactory bulb (Luskin, 1993). Although, most
precursors die during the migration or within the olfactory
bulb, many survive, differentiate and functionally
integrate as granule cells or periglomerular interneurons.
In the mammalian foetal brain, NSCs are concentrated
in the olfactory bulb, ependyma of lateral ventricles, SVZ,
hippocampus, cerebral cortex, cerebellum and spinal cord
(NIH Report, 2001b). In the human adult, stem cells persist
in the SVZ, subgranular zone and hilus of the dentate
gyrus of the hippocampus and subcortical white matter
(Fig. 4). 
The SVZ of the lateral ventricles is the largest stem
cell niche in the adult brain. The stem cell role is ascribed
to the astrocytes just beneath the inner glial limiting
membrane (Quiñones-Hinojosa et al., 2007). Such
astrocytes acting as NSCs lack other vital astrocytic
functions, such as the ability to regulate the extracellular
concentration of neurotransmitters. Ultrastructural
analysis has been used to classify the cellular
constituents of the SVZ (Doetsch et al., 1997). Type B
cells are the NSCs in the form of GFAP+ slowly dividing
astrocytes; culture of these cells yields colonies with
bipolar and multipolar neurons. The NSCs yield type C
cells, which are an amplifying intermediate between NSCs
and the type A cells, the neuroblasts, which are the most
abundant, highly proliferative, migratory cells.
Hippocampal NSCs give rise to neuroblasts, which
migrate into the granule cell layer of the dentate gyrus
where they differentiate into granule cells and send axons
to the CA3 region (Fig. 5). Unlike those in the SVZ,
hippocampal stem cells are not associated with ependyma
and they are not merely a source of new cells. The
hippocampal astrocytes functioning as NSCs also have
other astrocytic roles and may serve as a means of
communication between the mature and germinal zones
via processes, which penetrate the granule layer
intercalating among mature granule cells. Hence, the rate
of neurogenesis may be modulated as required. The
neurons thus, generated are functional and may be
involved for learning and memory (Praag et al., 2002).
Stress, opiate abuse, seizures and other factors can affect
the rate of neurogenesis in the dentate gyrus. 
Thus, there  is  a  significant  amount  of   NSCs  in
the   adult   brain,  especially  when   considering   the
size of the human lateral  ventricles. However, in neurolo-
gical diseases,  spontaneous  regeneration of structure
and function    are     generally    ineffective.  Nonetheless,
Fig. 4: Neural   stem   cell   niches  in  the adult brain
(Sanai et al., 2005)
Fig. 5: Demonstration of neurogenesis in the hippocampal
subgranular zone. A: Immature granule neurons
start appearing in the granular layer 8 days after
labelling  subgranular  zone  astrocytes. B:  After
30  days, labelled granule neurons in the dentate
gyrus show the characteristic dendritic
arborisations in  the  molecular  layer and an axon
(arrow) that projects to the CA3 region (Seri et al.,
2001)
NSCs can be a source of progenitor cells for future
neuroregenerative therapy. NSCs may also be a potential
source of brain tumours (Sanai et al., 2005).
THERAPEUTIC POTENTIALS
Cell  replacement  therapy  may  take  the form of an
in  vitro expansion and transplantation or the induction of
Int. J. Mol. Med. Adv. Sci., 4 (3): 62-73, 2008
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migration  of  endogenous  NSCs towards areas of However, the most likely disorders to give successful
damage or cell loss. NSCs  and  neuroblasts may show
low immunogenicity, thus being immunoprivileged on
transplantation,  allowing  the  possibility   for  using
NSCs allografts  to   treat   degenerative  brain conditions
(Hori et al., 2003). 
However, given the complexity of the cytoar-
chitecture of the CNS, one must assess the real potentials
and feasibility of stem cell therapy for neurological
disorders (Schwartz, 2007). It is important not to have a
simplistic idea that these cells might offer a fast and easy
treatment. Rather than replacing lost neurons in order to
re-establish a particular function, stem cell therapy can
become more clinically relevant if it is aimed to prevent or
minimise a particular disease process.
Various encouraging but inconsistent results have
been  obtained   for  Amyotrophic  Lateral Sclerosis
(ALS), Parkinson’s Disease (PD) and stroke, for instance
(Kerr et al., 2003; Akerud et al., 2002; Lévesque and
Neuman, 2002).
Kerr et al. (2003) have directed the differentiation of
hESCs and hEGCs to neuron-like cells by exposing the
stem cells to specific growth factors (e.g., retinoic acid,
EGF, BMP4, FGF2) to induce differentiation along the
ectodermal lineage. The neuron like cells were identified
and injected into the central canal of the spinal cord of a
murine model of ALS. A significant functional recovery
was observed. 
NSCs have been employed in models of PD and have
shown a capability to rescue and prevent further
degeneration of dopaminergic neurons (Akerud et al.,
2002). It seems that the transplanted NSCs themselves do
not give rise significantly to dopaminergic neurons but,
via the secretion of neuroprotective and growth factors,
stimulate the endogenous NSCs. On this principle, GDNF
was directly infused into the putamen of 5 PD patients in
a phase I trial (Gill et al., 2003). After 1 year a 61% increase
in the Barthel’s Index of activities of daily living (BAI)
score was noted. At 18 months PET showed a 28%
increase in putamen dopamine storage. Autologous NSC
transplantation in a PD patient gave a reduction of 80% in
symptoms after 1 year (Lévesque and Neuman, 2002). This
latter approach eliminates immune reactions at the site of
implantation; thus, it improves the likelihood of survival
of  the  surgically  implanted  cells and one can do without
immunosuppressants or steroids. It also minimizes risks of
transmission of infectious disease.
Animal  studies  have  revealed   that   adult NSCs
can  participate  in   repair   of   damage  after  stroke,
either via endogenous  NPCs or transplanted NSCs
(Arvidsson et al., 2002; Riess  et al., 2002). In both cases,
significant neuronal differentiation was observed and
postulated to offer promises for future therapy.
results are genetic leukodystrophies, Lysosomal Stroage
Diseases (LSDs) and invasive brain tumours (Schwartz,
2007). In such disorders, the restoration of neuronal
connections is not required and this makes it more likely
that a positive therapeutic outcome is obtainable.
DYSMYELINATING DISEASES
Myelination is essential for normal nervous
functions. Myelin insulates the axolemma and increases
the nerve conduction velocity by as much as 5-50 fold by
increasing the length constant and giving rise to saltatory
conduction (Guyton and Hall, 2006). In addition, this
saltatory conduction involves less ionic disturbances
when compared to continuous conduction since action
potentials occur only at the nodes of Ranvier; hence, less
metabolic energy is necessary for maintaining ionic
concentration differences. Myelination also allows
repolarisation to be achieved with small ionic transfers
since the myelin decreases membrane capacitance by
around 50 fold.
Dysmyelinating diseases include genetic leuko-
dystrophies and LSDs. These represent primary and
secondary defects in myelination, respectively. Common
neurological diseases, such as cerebral palsy, may also by
attributable to a perinatal loss of oligodendrocytes and
their precursors, which are particularly vulnerable to insult
(Kaye, 2001).
Oligodendrocyte Progenitor Cells (OPCs) can
remyelinate axons in dysmyelination (Windrem et al.,
2004). The adult forebrain white matter can be a source of
OPCs, which are identified as A2B5+, PSA-NCAM cells.
Windrem et al. (2004), transplanted OPCs to newborn
shiverer mice (Fig. 6). Shiverer mice are a model of
demyelination and show a generalised tremor on
locomotion (Chernoff, 1981). The outcome of OPC
transplantation differed between foetal and adult OPCs
(Table 2). Within white matter OPCs developed mostly as
oligodendrocytes,   while   in   grey matter astrocytes were
predominantly obtained. The resultant myelination
suggested normal structure and function. For instance,
the paranodal region of the nodes of Ranvier exhibited
Caspr, a member of the neurexin superfamily of
transmembrane proteins which mediate junction formation
between the axon and the paranodal loops of the
myelinating glia (Einheber et al., 1997). These junctional
complexes serve as attachment sites between the myelin
sheath and the axon, electrically insulating the periaxonal
space under the myelin from the ionic fluxes at the nodes
and preventing the lateral diffusion of membrane proteins
confining  them  to  their  appropriate   membrane  domain.
(b)
(c)
(a)
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Fig. 6: Electromicrographs of saggital sections through
the corpus callosum of adult shiverer mice. A:
Axons of shiverer mice typically have a single
loose wrapping of uncompacted myelin. B and C:
Sections of 16 week old shiverer mice implanted
with human OPCs shortly after birth. Dense
compact myelin sheaths with major dense lines
are now apparent (Windrem et al., 2004)
Table 2: Comparison between foetal and adult OPC properties upon
transplantation (Winderm et al., 2004)
Feature Foetal OPCs Adult OPCs
Rate of myelination Slow Fast
Time required for
dense myelination 3 months 1 month
Oligodendrocytes
generated/OPC Less More
Extent of migration Widespread, penetrating More restricted
grey matter to yield
astrocytes
Ideal applications Treatment of Replacing oligoden dro-
demyelination due to cytes after acute loss as
enxzymatic deficiency in sub-cortical infarts and
due to widespread post-inflammatory
dispersal and grey demyelinated lesions
matter invasion
Hence, OPCs offer an important treatment possibility
especially for genetic leukodystrophies such as Pelizaeus-
Merzbacher disease.
 LSDs result in death of oligodendrocytes due to the
toxic metabolites emanating from enzyme-deficient cells
(Windrem et al., 2004). Transplanted OPCs might be able
to infiltrate grey matter differentiating into astrocytes and
conveying the deficient enzyme via mannose-6-phosphate
receptor-mediated  endocytosis.  Even   small  increases
in lysosomal enzyme activity thus obtained can be
enough to prevent or slow down the disease process
(Jeyakumar et al., 2005). Hence, LSDs promise to be ideal
candidates of such gene therapy. Success of these
treatments postulates an early diagnosis and intervention
before substantial neurodegeneration occurs. Various
experiments on animal models of LSDs are documented in
the literature.
Niemann-pick  disease  results in lipid accumulation
in the brain, bone marrow, lungs, liver and spleen
(National  Institute  of  Neurological  Disorders and
Stroke, 2007a). Types A and B of the disease are due to
sphingomyelinase deficiency. Type A is the commonest
and occurs in infants. Neurological signs may include
incoordination and learning difficulties. Management and
prognosis are very poor; type A disease has no effective
treatment  and  is  invariably  fatal. In a murine model of
the  disease,  mesenchymal  stem  cells engineered to
over-express acid sphingomyelinase have been employed
successfully to delay neurological abnormalities and
extend lifespan (Jin et al., 2002). 
Experiments  along  these   lines   for   the  treatment
of Krabbe’s  disease  have also been performed
(Pellegatta et al., 2006; Escolar et al., 2005). The disease
involves a galactocerebrosidase deficiency resulting in
various neurological symptoms, generally of infantile
onset (National Institute of Neurological Disorders and
Stroke, 2007b). There is no cure and the infantile disease
is generally fatal before the 2nd year of life. Neural
progenitor cells overexpressing galactocerebrosidase
were transplanted into twitcher mice (a murine model of
Krabbe’s disease). The neuroblasts showed positive
tropisms to sites of active demyelination. Unfortunately,
the cells were unable to survive at such foci due to the
inflammation. Conversely, Escolar et al. (2005) obtained
very positive results with allogenic umbilical cord blood
stem cell transplantation to infants with Krabbe’s disease.
Donor cell engraftment and survival were both 100% in
asymptomatic patients who thus, exhibited a slower
disease progression, with most of them showing normal
cognition and language skills. Similar treatment of
symptomatic patients resulted in 43% donor cell survival
with minimal neurologic improvement. This confirms that
such treatments should be initiated as early as possible in
order to achieve clinical benefits.
Similarly, a presyptomatic murine model of
Metachromatic Leukodystrophy (MLD) responded
positively to  OPC  engraftment (Givogri et al., 2006).
MLD is caused by a deficiency of arylsulfatase A
(National Institute of Neurological Disorders and Stroke,
2007c). The late infantile form of MLD is the most common
and symptoms include muscle wasting, weakness and
rigidity. This form of MLD is fatal by around the fifth year
of life. In the experiment by Givogri et al. (2006), the OPCs
incorporated within the white matter as myelinating
oligodendrocytes. The arylsulfatase A levels were thus
enhanced with a complete prevention of the characteristic
motor symptoms.
Much work is being focused on Multiple Sclerosis
(MS) due to its high incidence and prevalence (Riuzi and
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Agius, 2004). In Northern Europe, North America and anaplastic and highly infiltrative, invading deep into the
Australasia, about one of every 1000 citizens suffers from
MS; its typical juvenile-onset and prolonged course result
in such a high frequency of the disease. Current treatment
of MS involves management with six possible approved
pharmacological interventions, which do not reverse
damage already done by the disease process but slow
down relapses (FDA, 2005). The multifocal nature of the
disease makes it a difficult target for cell therapy.
However, NSCs were  successfully integrated in an animal
model of MS reducing astrogliosis, causing axonal
remyelination and slowing of further axonal loss, hence,
leading to a functional recovery (Pluchino et al., 2004). It
seems that the NSCs give rise to OPCs and also remain
undifferentiated to act as local immune suppressants by
inducing apoptosis of T  cells, which enter the CNSH
(Pluchino et al., 2004). This effect decreases disease
progression by preventing the triggering cause of the
demyelination and axonal loss. Thus, MS offers
therapeutic potential but its intermittent nature, variable
anatomical disease localisation and accompanying axonal
damage are major hurdles to overcome. The capability of
stem cells to home to areas of injury is an important asset
in this regards.
In order to bring stem cell therapy into standard
practice in the treatment of dysmyelination, one has to
establish how much cells need to be  used,  where they
are to be delivered and the time frames for treatment
(Windrem et al., 2004). cytosine deaminase (Fig. 7). It is suggested that the
INVASIVE BRAIN TUMOURS
Brain tumours account for 85-90% of all primary CNS
tumours (National Cancer Institute, 2008). According to
the, Central Brain Tumour Registry of the United States,
the incidence rate of malignant brain tumours is
7.4/100,000 person years (Schiff and O’Neill, 2005). The
ratio of brain metastases to primary neoplasms is around
10-1; 20-40% of cancer patients develop brain metastases
and brain metastases are multiple in more than 70% of
cases. From the epidemiology and end results registry
1973-2002 data, the 5 year relative survival rates following
diagnosis of malignant CNS tumour are 28.1% for males
and 30.5% for females.
Tumours of the nervous system cannot be classified
according to the TNM system, since the tumour size is
relatively irrelevant, lymphatic spread cannot occur and
death generally ensues before metastatization can occur
(National Cancer Institute, 2008). The WHO classification
is employed whereby the tumours are classified primarily
by  their  cellular  origin  and  graded according to the
level  of  malignancy  from  grade  I  to  IV,  grade  IV being
parenchyma. The most common type of brain tumour is
the glioblastoma multiforme. It is an astrocytic grade IV
tumour and accounts for around 15% of brain tumours. Its
peak incidence age range is 45-70 and survival with this
disease is less than a year.
Hence, brain neoplasia generally offers a bleak
prognosis in spite of radical resection techniques with
possible adjuvant radio-and chemotherapy. In addition,
the latter therapies are generally non-specific and cause
significant toxicity and potential cognitive impairment,
especially with supratentorial irradiation (Vigliani et al.,
1999).
Endogenous neural progenitors may be involved in
the defence against neoplasia. It has been demonstrated
that these cells migrate towards, surround and infiltrate an
experimentally induced primary tumour mass and tumour
satellites, decreasing the tumour mass and enhancing
survival (Glass et al., 2005). A decrease in this tropism, as
occurs with advancing age, was correlated with a
decreased survival. 
Stem cell therapy might offer a targeted treatment
alternative (Mapara et al., 2007). NSCs reach the
neoplastic cells even when transplanted at a distant
location from the tumour, such as in the contralateral
lateral ventricle/hemisphere parenchyma or even
intravascularly outside the CNS. This strong homing
ability is preserved with engineered cells expressing a
foreign gene of a potential therapeutic product such as
trophic signals are generated by the tumour itself since, it
was observed that NSC placement within the primary
tumour mass resulted in lack of NSC migration beyond the
tumour borders. Soluble proteins, cell adhesion molecules
and extracellular matrix components are probably involved
in the migratory ability of the stem cells.
For example, the CXCR4 is expressed by the NSCs
and SDF-1, a CXCR4 ligand, is produced by brain tumour
cells in correlation to their invasiveness (Ehtesham et al.,
2004). In fact, NSC migration is inhibited by neutralising
SDF-1 and NSCs weakly immunopositive for CXCR4 are
non-migratory. Interestingly, migrating NSCs are immature
astrocytes, while NSCs, which remain within the primary
tumour are more differentiated since they express a
proteome typical of functional astrocytes, including
EAAT1 and EAAT2.
The literature shows several instances whereby, the
survival of mice with intracranial glioma was enhanced by
transplantation of cytokine secreting NSCs. For example,
Benedetti et al. (2000) employed IL-4 secreting NSCs,
while IL-12 was used by Ehtesham et al. (2002) IL-12
caused more CD4+ and CD8+ T-cells to reach the
dispersed tumour cells and was also shown to have a
long-term anti-tumorigenic effect.
(b)(a)
(c) (d)
(e) (f)
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Fig. 7: The migratory capacity of NSCs in vitro and in vivo. A and B: Glioblastoma cells were plated at the periphery of
2 plates. Fibroblasts (A) and NSCs (B), engineered to express a green fluorescent protein, were placed at the
centre (arrowheads). After an incubation of 5 days NSCs migrated widely, compared with fibroblasts (A), which
remained localized to their area of initial seeding C and D. Sections of brain under low (C) and high (D) power from
an adult rat killed 48 h after NSC injection into an established glioma; arrowheads demarcate approximate edges
of the tumour. NSCs (arrows) can be seen extensively distributed throughout the mass, interspersed among the
tumour cells. E: After 10 days, the NSCs (arrows) fail to penetrate beyong the tumour borderd (arrowheads).
However, NSCs appear to follow the invading tumour cell into surrounding tissue (upper right arrow). F: NSCs
migrate extensively following the invading glioblastoma cells
Another successful approach has employed cytosine very promising results have already been obtained; many
deaminase expressing  NSCs. Such cells would convert
the   systemically    administered    pyrimidine   analogue
5-fluorocytosine to 5-fluorouracil in very close proximity
to the tumour cells. A reduction of the tumour mass by
80% was  achieved  after  2 weeks of 5-fluorocytosine
administration. 
Mapara et al. (2007), also review other possible
treatment possibilities, such as virus and pro-apoptotic
protein delivery. Replication-conditional (i.e., able to
replicate and hence kill, only actively dividing  cells) HSV-
1 and TNF-Related Apoptosis Inducing Ligand (TRAIL)
are considered to be promising possible approaches. 
CONCLUSION
Stem cell research is likely to translate into new
therapeutic strategies. As regards neurological diseases,
diseases, which at present have a poor prognosis and
treatment might be satisfactorily managed with stem cell
therapy. For this to become a reality, the properties of
stem cells have to be unravelled to a greater depth, more
clinical trials need to be initiated to test the potentiality of
these novel approaches and ethical issues have to be
circumvented. 
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